Viral Pharyngitis
Conditions
Keywords
CPC, viral upper-respiratory infections
Brief summary
This is a randomized, controlled clinical trial with two parallel groups in which 150 volunteers (75 per group) will receive either VITIS CPC Protect® mouthwash (Mouthwash with cetylpyridinium chloride (CPC) as an anti-plaque antiseptic at a concentration of 0.07%) or mouthwash without cetylpyridinium chloride, as control group Subjects included in the study will be followed for 90 days. Symptoms associated with vURTIs (viral upper respiratory tract infections) should be recorded, when they appear, to determine the existence of viral infections of the upper respiratory tract. Symptoms and adverse effects will be recorded when the episode occurs. The assignment as VURIs will be made by the investigator once the diaries have been completed, or during the symptoms if possible.
Detailed description
This is a randomized, controlled clinical trial with two parallel groups in which 150 volunteers (75 per group) will be included. Allocation ratio (1:1). The trial will be offered to subjects who live in a nursing home and who can perform mouthwashes themselves or to whom healthcare professionals can apply the product. Subjects included in the study will be followed for 90 days. Symptoms associated with vURTI should be recorded, when they appear, to determine the existence of viral infections of the upper respiratory tract. If such an infection exists (when three of the following symptoms are present: fever over 37º, non-productive cough, sore throat, runny nose, nasal congestion or malaise) the degree of severity will be determined and recorded. Symptoms and adverse effects will be recorded when the episode occurs. The assignment as vURTI will be made by the investigator once the diaries have been completed, or during the symptoms if possible. Follow-up visits will be conducted fortnightly
Interventions
DRUGCPC mouthwash
0.07% CPC mouthwash
DRUGPlacebo
placebo of the CPC mouthwash
Sponsors
Methodex
Dentaid SL
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
65 Years to 100 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects admitted to nursing home * Subjects who have had a washing period of 2 months since the last use with mouthwashes. * \> age 65 * Subjects who are able to do mouthwashes or receive oral hygiene by caregivers * Delivery of the Participant Information Sheet (HIP) and signing of the Informed Consent (IC) to subjects or legal guardians of the subjects who agree to participate.
Exclusion criteria
* Subjects who are suffering from an upper or lower airway infection at the time of recruitment * Subjects who are physically or psychologically unable to perform mouthwashes or receive oral hygiene with gauze or cotton soaked in antiseptic * Subjects who have used oral antiseptics continuously in the past month * Use of oral hygiene measures outside the study conditions * Subjects who frequent residences, but are not admitted (e.g. day centre) Subjects or legal guardians of subjects who do not provide their IC to participate Subjects who have a registered allergy to the product or to the excipients of the product.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| occurrence of vURTI episodes | 3 months | the occurrence or non-occurrence of vURTI episodes. VURI is considered when three of the following symptoms are present: Fever over 37º; Non-productive cough; Sore throat; Rhinorrhoea; Nasal congestion; Discomfort |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| description of vURTI | 3 months | number of vURTI |
| oral health | 3 months | presence of gingival inflammation, |
Countries
Spain
Outcome results
None listed